COHANCE444.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹16,987 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity14.6414.554.444.44
Return on Assets13.328.732.622.62
Return on Capital Employed16.3611.164.714.71
Return on Invested Capital20.5013.964.473.14
Margins
EBITDA Margin38.6031.3318.8215.91
Operating Margin33.4124.8610.5610.56
Incremental Operating Margin-36.59-5.42
Pretax Margin38.5928.729.136.10
Net Income Margin28.5622.116.623.90
Net Income to Common Margin0.0022.377.905.76
FCF Margin29.1711.066.546.54
Additional
Effective Tax Rate25.9823.0127.4936.08
Sustainable Growth Rate14.6414.554.444.44
Incremental Operating Margin %-36.59-5.42-11.46
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.